Published in Vaccine Weekly, June 21st, 2006
The presentation took place at the Vaccine Discovery and Commercialization Conference in Philadelphia.
Bell provided an in-depth review of data presented earlier this month from three BioVant-adjuvanted flu vaccine preclinical studies using the M1 protein, H3N1 and H5N1 antigens. Results showed that BioVant effectively...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.